Apogenix GmbH of Germany has received €2.3 million from the German government to explore a new indication for its lead cancer product, APG101, which is a fusion protein. The new indication is myelodysplastic syndromes (MDS). ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
